{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:34:01Z","timestamp":1769506441779,"version":"3.49.0"},"reference-count":40,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Tropical Med Int Health"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Drug\u2010resistant tuberculosis remains a major public health challenge in Lao PDR, with low second\u2010line treatment uptake and suboptimal outcomes. To improve effectiveness, safety, and tolerability, a shorter all\u2010oral regimen for multidrug\u2010 and rifampicin\u2010resistant tuberculosis (MDR\/RR\u2010TB) was introduced under the TDR Short, all\u2010Oral Regimens for Rifampicin\u2010resistant Tuberculosis (ShORRT) initiative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective and prospective comparative cohort study was conducted across five drug\u2010resistant tuberculosis treatment centres from January 2020 to December 2023. Two programmatic cohorts were analysed during partially overlapping calendar periods: a standard injectable\u2010containing regimen cohort and an all\u2010oral regimen cohort. Outcomes were assessed at the end of treatment and 12\u2009months post\u2010treatment. Safety was evaluated through adverse events, including serious adverse events and adverse events of special interest. Health\u2010related quality of life was measured using EQ\u20105D\u20105L and EQ\u2010VAS tools.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 126 participants, 65 received the all\u2010oral regimen and 61 the standard regimen. Treatment success was higher in the all\u2010oral group (90.8% vs. 80.3%), with lower mortality (7.5% vs. 16.4%) and fewer serious adverse events (12.3% vs. 19.7%). Anaemia was more common in the all\u2010oral group (46.2%), while hepatotoxicity and QTcF prolongation were more frequent in the standard group. Both groups showed improvements in health\u2010related quality of life, but greater recovery in mobility, daily activities, and anxiety reduction was observed in the all\u2010oral group. Between group differences did not reach statistical significance. No cases of tuberculosis recurrence were reported at 12\u2010month follow\u2010up in either group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this programmatic setting, the all\u2010oral, bedaquiline and linezolid\u2010based regimen demonstrated high effectiveness and acceptable safety. Non\u2010significant trends favoured the all\u2010oral regimen for treatment success, mortality, and quality of life, consistent with but not definitive for improved outcomes. These findings support the transition to all\u2010oral regimens as the preferred approach for drug\u2010resistant tuberculosis care, while acknowledging the observational design and limited power.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/tmi.70041","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T02:15:59Z","timestamp":1758852959000},"page":"1340-1353","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["All\u2010Oral Shorter Treatment Regimens for Multidrug\u2010 and Rifampicin\u2010Resistant Tuberculosis: Evaluating Their Effectiveness, Safety, and Impact on the Quality of Life of\u00a0Patients in Lao\n                    <scp>PDR<\/scp>"],"prefix":"10.1111","volume":"30","author":[{"given":"Vibol","family":"Iem","sequence":"first","affiliation":[{"name":"Centre for Tuberculosis Research Liverpool School of Tropical Medicine  Liverpool UK"},{"name":"Office of the WHO Representative in Lao PDR  Vientiane Lao PDR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakhone","family":"Suthepmany","sequence":"additional","affiliation":[{"name":"National Tuberculosis Control Center  Vientiane Lao PDR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vongkham","family":"Inthavong","sequence":"additional","affiliation":[{"name":"National Tuberculosis Control Center  Vientiane Lao PDR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anousone","family":"Sisouvanh","sequence":"additional","affiliation":[{"name":"National Tuberculosis Control Center  Vientiane Lao PDR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khamloun","family":"Choumlivong","sequence":"additional","affiliation":[{"name":"Sethathirath Hospital  Vientiane Lao PDR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Hyun","family":"Oh","sequence":"additional","affiliation":[{"name":"World Health Organization Regional Office for the Western Pacific  Manila Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"du Cros","sequence":"additional","affiliation":[{"name":"Burnet Institute  Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatimata Bintou","family":"Sall","sequence":"additional","affiliation":[{"name":"Special Programme of Research and Training in Tropical Diseases (TDR) World Health Organization  Geneva Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne S.","family":"Merle","sequence":"additional","affiliation":[{"name":"Special Programme of Research and Training in Tropical Diseases (TDR) World Health Organization  Geneva Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Sebert","sequence":"additional","affiliation":[{"name":"Office of the WHO Representative in Lao PDR  Vientiane Lao PDR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donekham","family":"Inthavong","sequence":"additional","affiliation":[{"name":"National Tuberculosis Control Center  Vientiane Lao PDR"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"World Health Organization \u201cGlobal Tuberculosis Report \u201d2024."},{"key":"e_1_2_11_3_1","volume-title":"Rapid \u0421ommunication: Key Changes to Treatment of Multidrug\u2010And Rifampicin\u2010Resistant Tuberculosis (MDR\/RR\u2010TB)","author":"World Health Organization","year":"2018"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002595"},{"key":"e_1_2_11_5_1","unstructured":"World Health Organization \u201cAddressing TB Comorbidities and Health\u2010Related Risk Factors \u201d2023."},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00389-2"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119430"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0080-2015"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(23)00217-3"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.13205"},{"key":"e_1_2_11_11_1","unstructured":"TDR \u201cShORRT Initiative \u201d2019."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2019.07.005"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-016-0389-9"},{"key":"e_1_2_11_14_1","unstructured":"Organization W.H \u201cDefinitions and Reporting Framework for\u00a0Tuberculosis\u20132013 Revision: Updated December 2014 and January 2020 in Definitions and Reporting Framework for Tuberculosis\u20132013 Revision: Updated December 2014 and January 2020 \u201d2013."},{"key":"e_1_2_11_15_1","unstructured":"US Department of Health Human Services National Institutes of Health National Institute of Allergy Infectious Diseases Division of Aids Division of AIDS (DAIDS) \u201cTable for Grading the Severity of Adult and Pediatric Adverse Events Corrected \u201d2017."},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-018-1077-6"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-10417-w"},{"key":"e_1_2_11_20_1","unstructured":"R Core Team \u201cR Foundation for Statistical Computing: Vienna Austria \u201d2021."},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/105294199277860"},{"issue":"2","key":"e_1_2_11_22_1","first-page":"110","article-title":"Responsiveness and Minimal Clinically Important Difference for the EQ\u20105D in Chronic Rhinosinusitis","volume":"57","author":"Hoehle L. P.","year":"2019","journal-title":"Rhinology"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-024-02272-9"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy727"},{"issue":"9","key":"e_1_2_11_26_1","first-page":"1522","article-title":"The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)\u2013based Regimens for Rifampicin\u2010Resistant Tuberculosis in Non\u2010Trial Settings\u2014A Prospective Cohort Study in Belarus and Uzbekistan","volume":"68","author":"Sinha A.","year":"2025","journal-title":"Clinical Infectious Diseases"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02544-2020"},{"issue":"7","key":"e_1_2_11_28_1","first-page":"622","article-title":"Hearing Loss and Nephrotoxicity in Long\u2010Term Aminoglycoside Treatment in Patients With Tuberculosis","volume":"6","author":"De Jager P.","year":"2002","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161207779313731"},{"issue":"1","key":"e_1_2_11_30_1","first-page":"119","article-title":"Linezolid for Drug\u2010Resistant Pulmonary Tuberculosis","volume":"13","author":"Singh B.","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"e_1_2_11_31_1","first-page":"603","article-title":"Systematic Review and Meta\u2010Analysis of the Efficacy and Safety of Therapy With Linezolid Containing Regimens in the Treatment of Multidrug\u2010Resistant and Extensively Drug\u2010Resistant Tuberculosis","volume":"7","author":"Zhang X.","year":"2015","journal-title":"Journal of Thoracic Disease"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0267-y"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00537-2018"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488612802715735"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202311-2004OC"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0468"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2608.191499"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.12701\/yujm.2020.00626"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202107-1779OC"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202410-2096ST"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad177"}],"container-title":["Tropical Medicine &amp; International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tmi.70041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T04:01:59Z","timestamp":1764820919000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tmi.70041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/tmi.70041"],"URL":"https:\/\/doi.org\/10.1111\/tmi.70041","archive":["Portico"],"relation":{},"ISSN":["1360-2276","1365-3156"],"issn-type":[{"value":"1360-2276","type":"print"},{"value":"1365-3156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"2025-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}